H. Bauly

Absorption, distribution, metabolism, and excretion (ADME) of 14C-sonidegib (LDE225) in healthy volunteers

M. Zollinger, E. Hurh, C. Emotte, 2014, Cancer Chemotherapy and Pharmacology.

Health‐related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO‐2 trial

P. Neven, M. Piccart, G. Hortobagyi, 2013, Cancer.

Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2

M. Piccart, G. Hortobagyi, J. Baselga, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

3LBA Everolimus Added to Exemestane Reduced Bone Markers and Disease Progression in Bone in Postmenopausal Women with Advanced Breast Cancer: Updated Results From the BOLERO-2 Trial

M. Piccart, G. Hortobagyi, J. Baselga, 2012 .

Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2.

M. Piccart, G. Hortobagyi, J. Baselga, 2014 .